SonoThera Secures $125M: Ultrasound Reshapes Genetic Medicine
June 16, 2026, 10:14 pm
Location: United States, Florida, Saint Petersburg
Employees: 11-50
Founded date: 2014
SonoThera, a biotechnology pioneer, just closed a significant Series B funding round. The South San Francisco-based firm secured $125 million. This oversubscribed financing fuels its revolutionary nonviral genetic medicine platform. The investment accelerates key programs. These target Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD). Funds will drive these therapies into clinical trials. SonoThera's technology offers a new path. It overcomes long-standing challenges in gene delivery.
The company focuses on a unique approach. It employs ultrasound-mediated nonviral genetic medicines. This platform integrates two proprietary technologies: RIPPLE and PORE. RIPPLE facilitates ultrasound delivery. PORE handles payload engineering. Together, they enable targeted and redosable genetic therapies. This system allows for precise, durable gene expression. It works across multiple tissues.
Genetic medicine faces significant hurdles. Viral delivery methods have limitations. These include payload size restrictions. Immune responses pose another challenge. Repeat dosing is often impossible. SonoThera's platform tackles these issues directly. It avoids viral vectors entirely. This eliminates many safety and immunogenicity concerns. The technology broadens the potential of gene therapy. It supports DNA and RNA therapeutics. It also facilitates gene editing and gene silencing applications.
Preclinical data demonstrates powerful capabilities. SonoThera's platform achieves targeted delivery. It delivers to skeletal muscle, heart, liver, and kidney. Adipose tissue and brain also see successful delivery. The system handles large genetic payloads. Full-length dystrophin, crucial for DMD, has been delivered. RNA-based payloads for gene silencing also show success. These achievements pave the way for human trials.
Duchenne muscular dystrophy (DMD) is a devastating genetic disease. It causes progressive muscle degeneration. Current treatments offer limited options. Autosomal dominant polycystic kidney disease (ADPKD) leads to kidney cysts. It often results in kidney failure. SonoThera aims to bring new hope to patients. Its lead programs target these serious conditions. Clinical trials for DMD are anticipated to start in 2027. This marks a critical milestone.
The financing round saw strong participation. Vida Ventures led the investment. Other new investors joined. These include ARK Invest and CureDuchenne Ventures. Leaps by Bayer and Otsuka Pharmaceutical also participated. SymBiosis, UCB Ventures SA, and Vivo Capital contributed. Existing investors reaffirmed their support. ARCH Venture Partners was among them. Alexandria Venture Investments, Duquesne Family Office, and Illumina Ventures also participated. Johnson & Johnson Innovation – JJDC, Inc., Medical Excellence Capital, RA Capital, and Vertex Ventures HC also invested further. This diverse group reflects confidence in SonoThera's vision.
The funding also brought new leadership. Rajul Jain, M.D., from Vida Ventures, joined the board. Rakhshita Dhar, M.S., from Leaps by Bayer, also joined. These additions bring valuable expertise. They will guide SonoThera's strategic growth.
Proceeds from the Series B funding will be deployed strategically. The company will advance its DMD program into the clinic. Its ADPKD program will also enter clinical stages. Beyond these lead indications, SonoThera plans pipeline expansion. It aims to develop therapies across multiple organ systems. Scaling its proprietary technology platforms is another priority. This investment supports significant growth.
SonoThera's noninvasive procedure is groundbreaking. It utilizes widely available FDA-cleared diagnostic ultrasound systems. Commercially approved ultrasound contrast agents are also employed. The procedure can be completed swiftly. It often takes one hour or less. Patients could undergo this as an outpatient procedure. This ease of use contrasts sharply with invasive viral gene therapy methods. It improves accessibility for patients.
The platform addresses critical unmet needs. Many genetic diseases lack effective treatments. Existing gene therapies have significant limitations. SonoThera’s approach expands therapeutic possibilities. It enables precise and durable gene expression. It also allows for repeatable dosing. This is a major advantage over viral vectors. Viral vectors often trigger immune responses. This prevents re-administration. SonoThera's technology bypasses this hurdle.
The company's mission is clear. It seeks to broaden genetic medicine's reach. It aims to deliver safer, more effective therapies. Its South San Francisco location places it in a biotech hub. This offers access to top talent and resources. The $125 million investment validates its scientific rigor. It confirms its potential to transform medicine.
SonoThera is poised for rapid advancement. The shift to clinical trials is imminent. The focus on DMD and ADPKD is strategic. These diseases represent high unmet medical need. The platform’s versatility is key. It can deliver various genetic payloads. This flexibility allows for diverse therapeutic applications. It promises solutions for complex genetic disorders. The future of genetic medicine looks brighter. SonoThera leads this charge.
The company focuses on a unique approach. It employs ultrasound-mediated nonviral genetic medicines. This platform integrates two proprietary technologies: RIPPLE and PORE. RIPPLE facilitates ultrasound delivery. PORE handles payload engineering. Together, they enable targeted and redosable genetic therapies. This system allows for precise, durable gene expression. It works across multiple tissues.
Genetic medicine faces significant hurdles. Viral delivery methods have limitations. These include payload size restrictions. Immune responses pose another challenge. Repeat dosing is often impossible. SonoThera's platform tackles these issues directly. It avoids viral vectors entirely. This eliminates many safety and immunogenicity concerns. The technology broadens the potential of gene therapy. It supports DNA and RNA therapeutics. It also facilitates gene editing and gene silencing applications.
Preclinical data demonstrates powerful capabilities. SonoThera's platform achieves targeted delivery. It delivers to skeletal muscle, heart, liver, and kidney. Adipose tissue and brain also see successful delivery. The system handles large genetic payloads. Full-length dystrophin, crucial for DMD, has been delivered. RNA-based payloads for gene silencing also show success. These achievements pave the way for human trials.
Duchenne muscular dystrophy (DMD) is a devastating genetic disease. It causes progressive muscle degeneration. Current treatments offer limited options. Autosomal dominant polycystic kidney disease (ADPKD) leads to kidney cysts. It often results in kidney failure. SonoThera aims to bring new hope to patients. Its lead programs target these serious conditions. Clinical trials for DMD are anticipated to start in 2027. This marks a critical milestone.
The financing round saw strong participation. Vida Ventures led the investment. Other new investors joined. These include ARK Invest and CureDuchenne Ventures. Leaps by Bayer and Otsuka Pharmaceutical also participated. SymBiosis, UCB Ventures SA, and Vivo Capital contributed. Existing investors reaffirmed their support. ARCH Venture Partners was among them. Alexandria Venture Investments, Duquesne Family Office, and Illumina Ventures also participated. Johnson & Johnson Innovation – JJDC, Inc., Medical Excellence Capital, RA Capital, and Vertex Ventures HC also invested further. This diverse group reflects confidence in SonoThera's vision.
The funding also brought new leadership. Rajul Jain, M.D., from Vida Ventures, joined the board. Rakhshita Dhar, M.S., from Leaps by Bayer, also joined. These additions bring valuable expertise. They will guide SonoThera's strategic growth.
Proceeds from the Series B funding will be deployed strategically. The company will advance its DMD program into the clinic. Its ADPKD program will also enter clinical stages. Beyond these lead indications, SonoThera plans pipeline expansion. It aims to develop therapies across multiple organ systems. Scaling its proprietary technology platforms is another priority. This investment supports significant growth.
SonoThera's noninvasive procedure is groundbreaking. It utilizes widely available FDA-cleared diagnostic ultrasound systems. Commercially approved ultrasound contrast agents are also employed. The procedure can be completed swiftly. It often takes one hour or less. Patients could undergo this as an outpatient procedure. This ease of use contrasts sharply with invasive viral gene therapy methods. It improves accessibility for patients.
The platform addresses critical unmet needs. Many genetic diseases lack effective treatments. Existing gene therapies have significant limitations. SonoThera’s approach expands therapeutic possibilities. It enables precise and durable gene expression. It also allows for repeatable dosing. This is a major advantage over viral vectors. Viral vectors often trigger immune responses. This prevents re-administration. SonoThera's technology bypasses this hurdle.
The company's mission is clear. It seeks to broaden genetic medicine's reach. It aims to deliver safer, more effective therapies. Its South San Francisco location places it in a biotech hub. This offers access to top talent and resources. The $125 million investment validates its scientific rigor. It confirms its potential to transform medicine.
SonoThera is poised for rapid advancement. The shift to clinical trials is imminent. The focus on DMD and ADPKD is strategic. These diseases represent high unmet medical need. The platform’s versatility is key. It can deliver various genetic payloads. This flexibility allows for diverse therapeutic applications. It promises solutions for complex genetic disorders. The future of genetic medicine looks brighter. SonoThera leads this charge.